Hepatic Arterial Infusion Chemotherapy with Cisplatin for TACE-Refractory or -Ineligible Hepatocellular Carcinoma with Child-Pugh Score of 8 or Above

Authors Information
Article Notes and Dates
To Cite : Moriguchi M, Aramaki T, Yoza K, Iwai K, Sato R, et al. Hepatic Arterial Infusion Chemotherapy with Cisplatin for TACE-Refractory or -Ineligible Hepatocellular Carcinoma with Child-Pugh Score of 8 or Above, Hepat Mon. 2017 ;17(2):e43627. doi: 10.5812/hepatmon.43627.
Copyright: Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. The Lancet. 2002; 359(9319): 1734-9[DOI]
  • 2. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19(3): 329-38[DOI][PubMed]
  • 3. Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: The japan society of hepatology 2013 update (3rd jsh-hcc guidelines). Hepatol Res. 2015; 45(2)[DOI]
  • 4. Kudo M, Matsui O, Izumi N, Kadoya M, Okusaka T, Miyayama S, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology. 2014; 87 Suppl 1: 22-31[DOI][PubMed]
  • 5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4): 378-90[DOI][PubMed]
  • 6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10(1): 25-34[DOI]
  • 7. Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Saito T, Motoyama T, et al. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs. 2015; 33(3): 729-39[DOI][PubMed]
  • 8. Kim HY, Park JW, Joo J, Kim H, Woo SM, Lee WJ, et al. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. J Gastroenterol Hepatol. 2013; 28(11): 1756-61[DOI][PubMed]
  • 9. Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res. 2008; 38(5): 474-83[DOI][PubMed]
  • 10. Ikeda M, Okusaka T, Furuse J, Mitsunaga S, Ueno H, Yamaura H, et al. A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 2013; 72(2): 463-70[DOI][PubMed]
  • 11. Iwasa S, Ikeda M, Okusaka T, Ueno H, Morizane C, Nakachi K, et al. Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Jpn J Clin Oncol. 2011; 41(6): 770-5[DOI][PubMed]
  • 12. Liver Cancer Study Group of Japan . The general rules for the clinical and pathological study of primary liver cancer. 1992; : 15
  • 13. Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, et al. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer. 2014; 3(3-4): 458-68[DOI][PubMed]
  • 14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3): 205-16[PubMed]
  • 15. Miyaki D, Aikata H, Honda Y, Naeshiro N, Nakahara T, Tanaka M, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification. J Gastroenterol Hepatol. 2012; 27(12): 1850-7[DOI][PubMed]
  • 16. Sangro B, Raoul JL, Piscaglia F, Mazzaferro V, Galle PR, Dufour JF, et al. Heterogeneity of patients with intermediate (bclc b) hepatocellular carcinoma: Proposal for a subclassification to facilitate treatment decisions. Seminars in Liver Disease. 2013; 32(4): 348-59[DOI]
  • 17. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010; 33(1): 41-52[DOI][PubMed]
  • 18. Hucke F, Pinter M, Graziadei I, Bota S, Vogel W, Muller C, et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol. 2014; 61(6): 1287-96[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check